Home › Companies › X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. (XFOR) proxy voting records
How asset managers voted at X4 Pharmaceuticals, Inc.’s shareholder meetings, one page per
proxy season, compiled from the votes funds and managers report on SEC Form N-PX and
the company’s own results on Form 8-K.
- TickerXFOR
- CUSIP issuer number98420X
- SEC CIK1501697
Recent shareholder votes
- May 11, 2026 annual meeting (2025-2026 proxy season): 5 items in X4 Pharmaceuticals, Inc.'s official results (Form 8-K, filed May 12, 2026); lowest support 93% of votes cast (Approval, on a non-binding, advisory basis of the compensation…). Full results and how funds voted.
- June 9, 2025 annual meeting (2024-2025 proxy season): 3 items in X4 Pharmaceuticals, Inc.'s official results (Form 8-K, filed June 11, 2025); lowest support 64% of votes cast (Elect Director: R. Keith Woods). Full results and how funds voted.
- April 17, 2025 special meeting (2024-2025 proxy season): 1 item in X4 Pharmaceuticals, Inc.'s official results (Form 8-K, filed April 18, 2025); lowest support 82% of votes cast (The approval of an amendment to our Restated Certificate of…). Full results and how funds voted.
- June 10, 2024 annual meeting (2023-2024 proxy season): 5 items in X4 Pharmaceuticals, Inc.'s official results (Form 8-K, filed June 11, 2024); lowest support 88% of votes cast (Elect Director: David McGirr, M.B.A.). Full results and how funds voted.
Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.
Proxy seasons
Earlier seasons list this company under the name
X4 PHARMACEUTICALS INC., as its holders filed it.
Explore X4 Pharmaceuticals, Inc. in the interactive database
The seasons are grouped by the issuer number in the company’s CUSIP, not by
its name. Ticker as listed by the SEC on November 6, 2026.
This page is rebuilt weekly; built November 9, 2026.